VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
NCT ID: NCT01528254
Last Updated: 2020-09-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
2004 participants
INTERVENTIONAL
2012-03-30
2019-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
NCT00106340
Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.
NCT03577184
Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes
NCT00382096
Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
NCT00099892
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)
NCT00728351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Run-in period: At Visit 2, in all eligible patients, metformin treatment was initiated and/or up-titrated. At the end of the 3-week run-in period, patients who were able to tolerate a total dose of at least 1000 mg and up to 2000 mg daily proceeded to randomization and started in Period 1.
* Period 1 (vildagliptin/metformin combination versus metformin): At Visit 3, patients were randomized 1:1 to one of the following study regimens:
* Metformin up to 1000 mg bid plus vildagliptin 50mg bid or
* Metformin up to 1000 mg bid plus matching placebo bid
The duration of Period 1 could differ between patients depending on the time when the second of two HbA1c measurements taken at two consecutive visits after randomisation confirmed HbA1c ≥ 7.0%.
• Period 2 (vildagliptin/metformin combination versus vildagliptin add-on to metformin): In the case of two consecutive HbA1c measurements ≥7.0% from two consecutive study visits during Period 1, patients who were randomised to the placebo arm in Period 1 received vildagliptin 50 mg bid. Patients who were randomised to the active vildagliptin 50 mg bid arm in Period 1 continued to receive vildagliptin 50 mg bid. All patients continued to take their metformin dose unchanged. Period 2 remained masked to the patient and both patients and investigators remained masked to the treatment allocation in Period 1.
If, during Period 2, therapy intensification was required in accordance with the local guidelines, the patient entered Period 3. The duration of Period 2 could differ between patients. End of Period 2 was considered when insulin treatment was initiated, or alternatively when the patient was discontinued because insulin treatment was not initiated in Period 3.
• Period 3 (insulin initiation): In Period 3, patients were to be initiated on open-label insulin. The study drug regimen continued unchanged and remained masked to the patient in Period 3 and both patients and investigators remained masked to the treatment allocation in Period 1.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vilda 50mg bid + metformin
Metformin + vildagliptin
vildagliptin
One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
Metformin
Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
Placebo + metformin
Metformin + Placebo of vildagliptin
Placebo of vildagliptin
Metformin
Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo of vildagliptin
vildagliptin
One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
Metformin
Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* glycosylated hemoglobin (HbA1c) ≥6.5% and ≤7.5% at Visit 1
* Treatment-naïve.
* Body mass index (BMI) ≥22 and ≤40 kg/m2 at Visit 1
Exclusion Criteria
* Fasting plasma glucose (FPG) ≥ 270 mg/dL (≥ 15.0 mmol/L)
* Previous or current participation in any vildagliptin clinical study.
* History of hypersensitivity to dipeptidyl peptidase-4 (DPP-4) inhibitors.
* Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
* Donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
San Isidro, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires F.D., Argentina
Novartis Investigative Site
Buenos Aires, , Argentina
Novartis Investigative Site
Corrientes, , Argentina
Novartis Investigative Site
Córdoba, , Argentina
Novartis Investigative Site
Brookvale, New South Wales, Australia
Novartis Investigative Site
Woy Woy, New South Wales, Australia
Novartis Investigative Site
Morayfield, Queensland, Australia
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Brasília, Federal District, Brazil
Novartis Investigative Site
Goiânia, Goiás, Brazil
Novartis Investigative Site
Curitiba, Paraná, Brazil
Novartis Investigative Site
Belém, Pará, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Mogi das Cruzes, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Smolyan, Bulgaria, Bulgaria
Novartis Investigative Site
Gabrovo, , Bulgaria
Novartis Investigative Site
Kazanlak, , Bulgaria
Novartis Investigative Site
Plovdiv, , Bulgaria
Novartis Investigative Site
Razgrad, , Bulgaria
Novartis Investigative Site
Rousse, , Bulgaria
Novartis Investigative Site
Sofia, , Bulgaria
Novartis Investigative Site
Sofia, , Bulgaria
Novartis Investigative Site
Sofia, , Bulgaria
Novartis Investigative Site
Bogota, Cundinamarca, Colombia
Novartis Investigative Site
Cartagena, Departamento de Bolívar, Colombia
Novartis Investigative Site
Baranquilla, , Colombia
Novartis Investigative Site
Bogotá, , Colombia
Novartis Investigative Site
Písek, Czech Republic, Czechia
Novartis Investigative Site
Prague, Czech Republic, Czechia
Novartis Investigative Site
Brandýs nad Labem, , Czechia
Novartis Investigative Site
Prague, , Czechia
Novartis Investigative Site
Santo Domingo, Republica Dominicana, Dominican Republic
Novartis Investigative Site
Santo Domingo, , Dominican Republic
Novartis Investigative Site
Saku, , Estonia
Novartis Investigative Site
Tallinn, , Estonia
Novartis Investigative Site
Tallinn, , Estonia
Novartis Investigative Site
Tallinn, , Estonia
Novartis Investigative Site
Tallinn, , Estonia
Novartis Investigative Site
Lahti, Suomi, Finland
Novartis Investigative Site
Kerava, , Finland
Novartis Investigative Site
Kouvola, , Finland
Novartis Investigative Site
Tampere, , Finland
Novartis Investigative Site
Hainstadt, Hainburg, Germany
Novartis Investigative Site
Aschaffenburg, , Germany
Novartis Investigative Site
Cologne, , Germany
Novartis Investigative Site
Dresden, , Germany
Novartis Investigative Site
Düsseldorf, , Germany
Novartis Investigative Site
Essen, , Germany
Novartis Investigative Site
Essen, , Germany
Novartis Investigative Site
Esslingen am Neckar, , Germany
Novartis Investigative Site
Fulda, , Germany
Novartis Investigative Site
Gelnhausen, , Germany
Novartis Investigative Site
Kamp-Lintfort, , Germany
Novartis Investigative Site
Ludwigshafen, , Germany
Novartis Investigative Site
Neuwied, , Germany
Novartis Investigative Site
Saint Ingbert - Oberwuerzbach, , Germany
Novartis Investigative Site
Wangen, , Germany
Novartis Investigative Site
Clinica, Departamento de Guatemala, Guatemala
Novartis Investigative Site
Guatemala City, , Guatemala
Novartis Investigative Site
Guatemala City, , Guatemala
Novartis Investigative Site
Hong Kong, , Hong Kong
Novartis Investigative Site
Zalaegerszeg, Zala County, Hungary
Novartis Investigative Site
Budapest, , Hungary
Novartis Investigative Site
Budapest, , Hungary
Novartis Investigative Site
Csongrád, , Hungary
Novartis Investigative Site
Eger, , Hungary
Novartis Investigative Site
Kalocsa, , Hungary
Novartis Investigative Site
Szeged, , Hungary
Novartis Investigative Site
Veszprém, , Hungary
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Kochi, Kerala, India
Novartis Investigative Site
Indore, Madhya Pradesh, India
Novartis Investigative Site
Pune, Maharashtra, India
Novartis Investigative Site
Pune, Maharashtra, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Jaipur, Rajasthan, India
Novartis Investigative Site
Jaipur, Rajasthan, India
Novartis Investigative Site
Chennai, Tamil Nadu, India
Novartis Investigative Site
Chennai, Tamil Nadu, India
Novartis Investigative Site
Chandigarh, , India
Novartis Investigative Site
Haifa, Israel, Israel
Novartis Investigative Site
Jerusalem, , Israel
Novartis Investigative Site
Kfar Saba, , Israel
Novartis Investigative Site
Rehovot, , Israel
Novartis Investigative Site
Sefad, , Israel
Novartis Investigative Site
Tel Aviv, , Israel
Novartis Investigative Site
Tel Giborim, Holon, , Israel
Novartis Investigative Site
Montichiari, BS, Italy
Novartis Investigative Site
Campobasso, CB, Italy
Novartis Investigative Site
Arenzano, GE, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Casorate Primo, PV, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Jelgava, LV, Latvia
Novartis Investigative Site
Liepāja, LV, Latvia
Novartis Investigative Site
Ogre, LV, Latvia
Novartis Investigative Site
Riga, LV, Latvia
Novartis Investigative Site
Riga, LV, Latvia
Novartis Investigative Site
Talsi, LV, Latvia
Novartis Investigative Site
Daugavpils, , Latvia
Novartis Investigative Site
Riga, , Latvia
Novartis Investigative Site
Riga, , Latvia
Novartis Investigative Site
Kaunas, LTU, Lithuania
Novartis Investigative Site
Vilnius, LT, Lithuania
Novartis Investigative Site
Jonava, , Lithuania
Novartis Investigative Site
Kaunas, , Lithuania
Novartis Investigative Site
Kaunas, , Lithuania
Novartis Investigative Site
Vilnius, , Lithuania
Novartis Investigative Site
Kota Bharu, Kelantan, Malaysia
Novartis Investigative Site
Kuala Lumpur, , Malaysia
Novartis Investigative Site
Kuala Lumpur, , Malaysia
Novartis Investigative Site
Mexico City, Mexico City, Mexico
Novartis Investigative Site
Mexico City, Mexico City, Mexico
Novartis Investigative Site
Mexico City, Mexico City, Mexico
Novartis Investigative Site
Cuautla, Morelos, Mexico
Novartis Investigative Site
Cuernavaca, Morelos, Mexico
Novartis Investigative Site
Aguascalientes, , Mexico
Novartis Investigative Site
Distrito Federal, , Mexico
Novartis Investigative Site
Durango, , Mexico
Novartis Investigative Site
Querétaro, , Mexico
Novartis Investigative Site
Enebakk, , Norway
Novartis Investigative Site
Fetsund, , Norway
Novartis Investigative Site
Hønefoss, , Norway
Novartis Investigative Site
Oslo, , Norway
Novartis Investigative Site
Spikkestad, , Norway
Novartis Investigative Site
Panama City, , Panama
Novartis Investigative Site
Panama City, , Panama
Novartis Investigative Site
Trujillo, La Libertad, Peru
Novartis Investigative Site
Chorrillos, Lima region, Peru
Novartis Investigative Site
Lima Cercado, Lima region, Peru
Novartis Investigative Site
Magdalena, Lima region, Peru
Novartis Investigative Site
San Isidro, Lima region, Peru
Novartis Investigative Site
San Martín de Porres, Lima region, Peru
Novartis Investigative Site
Arequipa, , Peru
Novartis Investigative Site
Marikina City, National Capital Region, Philippines
Novartis Investigative Site
Quezon City, National Capital Region, Philippines
Novartis Investigative Site
Pasay, Philippines, Philippines
Novartis Investigative Site
Marikina City, , Philippines
Novartis Investigative Site
Pasig, , Philippines
Novartis Investigative Site
San Juan City, , Philippines
Novartis Investigative Site
Poznan, , Poland
Novartis Investigative Site
Poznan, , Poland
Novartis Investigative Site
Poznan, , Poland
Novartis Investigative Site
Wroclaw, , Poland
Novartis Investigative Site
Zabrze, , Poland
Novartis Investigative Site
Oradea, Bihor County, Romania
Novartis Investigative Site
Oradea, Jud. Bihor, Romania
Novartis Investigative Site
Ploieşti, Jud. Prahova, Romania
Novartis Investigative Site
Bucharest, , Romania
Novartis Investigative Site
Bucharest, , Romania
Novartis Investigative Site
Bucharest, , Romania
Novartis Investigative Site
Timișoara, , Romania
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
N.Novgorod, , Russia
Novartis Investigative Site
Penza, , Russia
Novartis Investigative Site
Petrozavodsk, , Russia
Novartis Investigative Site
Ryazan, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saratov, , Russia
Novartis Investigative Site
Smolensk, , Russia
Novartis Investigative Site
Bratislava, Slovak Republic, Slovakia
Novartis Investigative Site
Košice, Slovak Republic, Slovakia
Novartis Investigative Site
Lučenec, Slovak Republic, Slovakia
Novartis Investigative Site
Námestovo, Slovak Republic, Slovakia
Novartis Investigative Site
Rožňava, Slovak Republic, Slovakia
Novartis Investigative Site
Šaľa, Slovak Republic, Slovakia
Novartis Investigative Site
Trebišov, Slovak Republic, Slovakia
Novartis Investigative Site
Žilina, Slovak Republic, Slovakia
Novartis Investigative Site
Banská Bystrica, , Slovakia
Novartis Investigative Site
Košice, , Slovakia
Novartis Investigative Site
Košice, , Slovakia
Novartis Investigative Site
Levice, , Slovakia
Novartis Investigative Site
Nové Zámky, , Slovakia
Novartis Investigative Site
Prešov, , Slovakia
Novartis Investigative Site
Sabinov, , Slovakia
Novartis Investigative Site
Sereď, , Slovakia
Novartis Investigative Site
Štúrovo, , Slovakia
Novartis Investigative Site
Žilina, , Slovakia
Novartis Investigative Site
Alberton, , South Africa
Novartis Investigative Site
Cape Town, , South Africa
Novartis Investigative Site
Durban, , South Africa
Novartis Investigative Site
Durban, , South Africa
Novartis Investigative Site
Gauteng, , South Africa
Novartis Investigative Site
Johannesburg, , South Africa
Novartis Investigative Site
Johannesburg, , South Africa
Novartis Investigative Site
Pretoria, , South Africa
Novartis Investigative Site
Pretoria, , South Africa
Novartis Investigative Site
Incheon, Gyeonggi-do, South Korea
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea
Novartis Investigative Site
Uijeongbu-si, Gyeonggi-do, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Seocho Gu, South Korea
Novartis Investigative Site
Daejeon, , South Korea
Novartis Investigative Site
Incheon, , South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Sant Adria Del Besos, Barcelona, Spain
Novartis Investigative Site
Santa Coloma de Gramanet, Barcelona, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Taichung, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Taoyuan District, , Taiwan
Novartis Investigative Site
Xindian District, , Taiwan
Novartis Investigative Site
Diskapi / Ankara, Turkey, Turkey (Türkiye)
Novartis Investigative Site
Adana, , Turkey (Türkiye)
Novartis Investigative Site
Antalya, , Turkey (Türkiye)
Novartis Investigative Site
Denizli, , Turkey (Türkiye)
Novartis Investigative Site
Istanbul, , Turkey (Türkiye)
Novartis Investigative Site
Izmir, , Turkey (Türkiye)
Novartis Investigative Site
Izmir, , Turkey (Türkiye)
Novartis Investigative Site
Kahramanmaraş, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tsotra F, Kappel M, Peristeris P, Bader G, Levi E, Lister N, Malhotra A, Ostwald DA. The societal impact of early intensified treatment in patients with type 2 diabetes mellitus. J Comp Eff Res. 2022 Nov;11(16):1185-1199. doi: 10.2217/cer-2022-0110. Epub 2022 Sep 28.
Vencio S, Manosalva JP, Mathieu C, Proot P, Lozno HY, Paldanius PM. Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study. Diabetol Metab Syndr. 2021 Jun 15;13(1):68. doi: 10.1186/s13098-021-00686-9.
Matthews D, Del Prato S, Mohan V, Mathieu C, Vencio S, Chan JCN, Stumvoll M, Paldanius PM. Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. Diabetes Ther. 2020 Nov;11(11):2465-2476. doi: 10.1007/s13300-020-00926-7. Epub 2020 Sep 25.
Matthews DR, Paldanius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18.
Matthews DR, Paldanius PM, Proot P, Foley JE, Stumvoll M, Del Prato S. Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes. Diabet Med. 2019 Apr;36(4):505-513. doi: 10.1111/dme.13886. Epub 2019 Feb 12.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-003712-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CLAF237A23156
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.